Breathtec Biomedical Inc. appointed Christopher Moreau as its CEO.
Moreau is the CEO of NASH Pharmaceuticals Inc., a privately held drug development company. He is also the former president and CEO of Miraculins Inc., where he helped raise over C$13 million to fund research and development for prostate cancer, skin cholesterol and type 2 diabetes.
Breathtec Biomedical is a Canadian company developing breath-analysis technology for the early screening of life-threatening diseases.
